Helix BioPharma Corp. is making headlines with a significant rise in stock price, reflecting investor optimism.
Helix BioPharma Corp. (HBP.TO) is up today, gaining 5.88% to close at CA$1.80. This increase is catching attention in the biotech sector, suggesting renewed investor interest and confidence in the company's future.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeAdvertisement
Market cap
$129.84M
52W high
$5.40
52W low
$1.10
1W change
+16.13%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 38.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+38.9% Upside
Current Price
C$1.80
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
41.2%
Annualized
90-Day Vol
61.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.15
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.91 | C$1.66 – C$2.20 |
| 60 trading days | C$2.03 | C$1.66 – C$2.48 |
| 90 trading days | C$2.15 | C$1.68 – C$2.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the growth potential in Helix BioPharma, especially as the company navigates the challenges in the biotech market.
Helix BioPharma's market cap reaches CA$137.48 million
With a market cap of CA$137.48 million, Helix BioPharma's stock performance today shows a growing interest in its potential within the biotech sector.
Bull case
The recent rise in stock price might indicate a positive shift in investor sentiment. This could be driven by strategic initiatives or upcoming developments that may strengthen the company's position in the market.
Bear case
Despite today's gains, Helix BioPharma still faces significant challenges in securing financing and advancing its projects, which could affect its future performance.
Advertisement
Stock Performance Overview
Helix BioPharma Corp. has seen a notable increase in its stock price today, rising by 5.88%. This brings the stock to a closing price of CA$1.80, marking a recovery in a tough market for biotech firms.
Market Sentiment and Future Prospects
The rise in Helix BioPharma's stock may signal a change in market sentiment, with investors responding to the company's ongoing efforts to secure financing and push its projects forward. However, the company still faces hurdles, including a competitive biotech landscape and the need for strategic partnerships.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
